The FDA has been granted TZP-102 a fast track designation because this drug candidate treats a serious or life-threatening condition and addresses an unmet medical need. In their approval letter, the FDA noted there are limited treatment options for diabetic gastroparesis and the agents currently available have serious side effects. If TZP-102 can succeed in the second clinical trials, it has the potential to be a blockbuster drug
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.